Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.
BACKGROUND
Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, occurs less commonly in infants. Historically, poorer outcomes have been reported for infants diagnosed with RMS than for older children.


METHODS
The authors analyzed the characteristics, treatment administered, outcomes, and patterns of failure for infants aged < 1 year with nonmetastatic RMS who received multimodal therapy on Intergroup Rhabdomyosarcoma Study (IRS) protocols IRS-IV, D9602, and D9803.


RESULTS
Seventy-six infants with nonmetastatic RMS were treated on the 3 protocols from 1991 to 2005. Their median age was 7.4 months (range, 0.1-12 months). Tumor histology included embryonal (57%), alveolar (21%), and undifferentiated sarcoma/other (22%). A parameningeal primary tumor site was less common in this infant cohort (3%) than in all patients who were treated on IRS-IV (25%). The estimated 5-year failure-free survival and overall survival rates (95% confidence interval [CI]) were 57% (95% CI, 44%-67%) and 76% (95% CI, 65%-85%), respectively, for infants compared with 81% (95% CI, 79%-83%) and 87% (95% CI, 85%-89%), respectively, for children ages 1 to 9 years. Twenty-three of 32 infants with treatment failure had local recurrence/progression with distant failure (n = 3) or without distant failure (n = 20). The overall local failure rate was 30%. The median time to treatment failure was 13 months. The failure-free survival rate was worse for infants who had IRS Group III tumors and for those who received less than protocol-recommended radiation therapy.


CONCLUSIONS
Infants with RMS appeared to have worse outcomes than older patients, in part because of high rates of local failure. The authors concluded that concerns regarding morbidity in infants and reluctance to use aggressive local control measures may lead to higher rates of local failure.
Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239-3098, USA. malempat@ohsu.edu
Suman
S
Malempati
David A
DA
Rodeberg
Sarah S
SS
Donaldson
Elizabeth R
ER
Lyden
James R
JR
Anderson
Douglas S
DS
Hawkins
Carola A S
CA
Arndt
D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D012208:Rhabdomyosarcoma / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery
J Clin Oncol. 1995 Mar;13(3):610-30
7884423
J Clin Oncol. 2011 Apr 1;29(10):1312-8
21357783
Cancer. 1986 Dec 15;58(12):2606-10
3779610
J Clin Oncol. 2009 Nov 1;27(31):5182-8
19770373
Pediatr Blood Cancer. 2004 Jan;42(1):64-73
14752797
Br J Cancer. 1977 Jan;35(1):1-39
831755
J Clin Oncol. 2001 Jun 15;19(12):3091-102
11408506
J Clin Oncol. 2006 Aug 20;24(24):3844-51
16921036
Cancer. 2003 May 15;97(10):2597-604
12733159
J Clin Oncol. 2004 May 15;22(10):1894-901
15143082
J Clin Oncol. 1988 Jan;6(1):51-5
2826715
J Clin Oncol. 1987 Jan;5(1):46-54
3543238
Pediatr Blood Cancer. 2010 Mar;54(3):341-3
19908300
J Clin Oncol. 2005 Jul 1;23(19):4363-71
15994146
Cancer. 1993 Mar 1;71(5):1904-22
8448756
Cancer. 1988 Jan 15;61(2):209-20
3275486
Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1239-46
10725637
J Clin Oncol. 2005 Apr 20;23(12):2618-28
15728225
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1177-84
16682130
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):333-8
20646841